Medigen Biotechnology Corp. (TPEX:3176)
Taiwan · Delayed Price · Currency is TWD 31.80
-0.25 (-0.78%)
Jul 30, 2026, 9:47 AM CST
Medigen Biotechnology Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,465 | 4,514 | 4,514 | 6,243 | 4,685 | 7,999 | |
Market Cap Growth | 2.89% | 0% | -27.70% | 33.24% | -41.43% | -2.78% |
Enterprise Value | 6,549 | 6,329 | 6,470 | 8,430 | 7,328 | 10,273 |
Last Close Price | 32.05 | 32.40 | 32.40 | 44.80 | 33.60 | 57.40 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 41.51 | 41.51 | 41.51 | 41.51 | 41.51 |
PS Ratio | 3.32 | 2.85 | 3.29 | 5.39 | 4.44 | 2.04 |
PB Ratio | 0.95 | 0.96 | 0.90 | 1.25 | 0.72 | 1.25 |
P/TBV Ratio | 3.18 | 3.10 | 3.05 | 4.20 | 2.25 | 3.52 |
P/FCF Ratio | - | - | - | - | - | 21.32 |
P/OCF Ratio | - | 111.32 | 119.03 | - | - | 15.44 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.87 | 4.00 | 4.71 | 7.28 | 6.94 | 2.62 |
EV/EBITDA Ratio | - | - | - | - | - | 10.62 |
EV/EBIT Ratio | - | - | - | - | - | 13.17 |
EV/FCF Ratio | - | - | - | - | - | 27.38 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.36 | 0.19 | 0.20 | 0.57 | 0.43 | 0.15 |
Debt / EBITDA Ratio | - | 57.31 | - | - | - | 1.02 |
Debt / FCF Ratio | - | - | - | - | - | 2.64 |
Net Debt / Equity Ratio | -0.24 | -0.33 | -0.31 | -0.34 | -0.36 | -0.31 |
Net Debt / EBITDA Ratio | 6.59 | 175.94 | 23.46 | 1.60 | 1.58 | -2.07 |
Net Debt / FCF Ratio | 6.07 | 50.90 | 83.67 | 3.18 | 1.84 | -5.35 |
Asset Turnover | 0.20 | 0.25 | 0.18 | 0.13 | 0.12 | 0.55 |
Inventory Turnover | 0.99 | 1.11 | 1.04 | 0.87 | 1.34 | 2.55 |
Quick Ratio | 4.41 | 3.80 | 3.19 | 1.81 | 5.32 | 3.60 |
Current Ratio | 5.41 | 4.68 | 3.96 | 2.05 | 6.40 | 4.62 |
Return on Equity (ROE) | -9.52% | -6.07% | -4.43% | -25.64% | -29.95% | 19.60% |
Return on Assets (ROA) | -2.96% | -1.52% | -1.78% | -8.33% | -11.46% | 6.79% |
Return on Invested Capital (ROIC) | -9.57% | -4.74% | -6.43% | -33.40% | -39.08% | 18.75% |
Return on Capital Employed (ROCE) | -5.20% | -2.90% | -3.80% | -21.50% | -18.70% | 10.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -5.92% | -2.41% | -4.54% | -8.99% | -14.42% | -0.66% |
FCF Yield | -4.20% | -0.69% | -0.41% | -8.68% | -27.46% | 4.69% |
Buyback Yield / Dilution | 0.03% | - | 0.03% | -0.16% | -0.11% | 0.01% |